Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

134.15
+1.020.77%
Volume:1.08M
Turnover:145.22M
Market Cap:19.66B
PE:13.26
High:135.69
Open:134.06
Low:132.93
Close:133.13
Loading ...

RBC Cuts Price Target on Biogen to $217 From $225, Keeps Outperform Rating

MT Newswires Live
·
25 Apr

Biogen Inc. Stock Rises Thursday, Still Underperforms Market

Dow Jones
·
25 Apr

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

Zacks
·
24 Apr

Mhra Approves First UK Treatment for Friedreich's Ataxia, Omaveloxolone

THOMSON REUTERS
·
23 Apr

Biogen Is Maintained at Buy by Goldman Sachs

Dow Jones
·
23 Apr

Goldman Sachs Adjusts Price Target on Biogen to $197 From $219, Maintains Buy Rating

MT Newswires Live
·
23 Apr

Biogen Is Maintained at Outperform by RBC Capital

Dow Jones
·
22 Apr

RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating

MT Newswires Live
·
22 Apr

U.S. RESEARCH ROUNDUP-Amazon, Comerica, United Airlines

Reuters
·
22 Apr

Biogen Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
22 Apr

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
18 Apr

Biogen Unlikely to Receive Boost from Leqembi Approval in EU -- Market Talk

Dow Jones
·
17 Apr

Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval

Dow Jones
·
16 Apr

Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
16 Apr

Biogen reports EC grants marketing authorization for Leqembi

TIPRANKS
·
16 Apr

Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

MT Newswires Live
·
16 Apr

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

Reuters
·
15 Apr

Goldman Sachs Adjusts Biogen's Price Target to $219 From $245, Keeps Buy Rating

MT Newswires Live
·
15 Apr

Biogen Inc. Stock Climbs 3.6%, Outperforms Competitors

Dow Jones
·
15 Apr

BUZZ-Potential EU approval for Biogen's Alzheimer's drug underway; shares rise

Reuters
·
14 Apr